Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says
This article was originally published in The Pink Sheet Daily
Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.
You may also be interested in...
Amgen's bundling of rebates for Aranesp, Neulasta and Neupogen have unfairly increased the anemia therapy's market share, the complaint alleges.
Anemia therapy should reverse a quarterly sales decline brought on by competition from Amgen, Johnson & Johnson maintains. Worldwide sales were up for the second quarter.
Procrit sales are the one weak spot in a strong quarter overall. J&J is moving away from its previous policy of retaining a "level playing field" between Procrit and Aranesp pricing; the strategy now is to have a "reasonably level playing field."